Investor puts P&G under pressure; AstraZeneca says virtual move provides real results; Par, Watson get generics nod;

@FiercePharma: Emerging-markets demand saves French plant where ‪Ipsen‬ makes primary care meds. News | Follow @FiercePharma

> FTC clearance has been given for activist investor William Ackman's Pershing Square to make a substantial investment in Procter & Gamble ($PG) Story

> Affymax ($AFFY) and partner Takeda Pharmaceutical have an agreement with Fresenius Medical Care to use their anemia drug Omontys in its U.S. dialysis centers. Story

> AstraZeneca ($AZN) says that its move to cut its 800-900 neuroscience staff and adopt a virtual external research unit of about 40 scientists is already bearing fruit. Story

> Watson Laboratories ($WCI) will immediately produce a generic version of Teva Pharmaceutical's ($TEVA)  contraceptive, Plan B One-Step. Item

> Par Pharmaceutical Companies ($PRX) has been given FDA permission to make a generic version of the blood pressure drug Trandate, which it says will be available in August. Item

> Congress digs deeper into how "fake pharmacies" are preying on drug shortages. Story

Biotech News

@FierceBiotech: GSK, ‪Theravance‬ hit up regulators for approval of key asthma/COPD drug. More | Follow @FierceBiotech

@JohnCFierce: AstraZeneca‬'s Link deal all about getting its new iMed - small, semi-virtual discovery unit - in gear. Wheelin/dealin. Item | Follow @JohnCFierce

@RyanMFierce: BB Biotech rejected unsolicited proposal to take co private, says shares bested the Swiss mkt. Is that enough? Release | Follow @RyanMFierce

> Acadia Pharmaceuticals ($ACAD) has scrapped development of a schizophrenia drug, AM-831, after the candidate missed the main goal of an early-stage study. Article

> Pharma services giant Quintiles has teamed up with healthcare tech provider Allscripts to develop clinical research software. Report

> Affymax's ($AFFY) shares jumped after the biotech and Takeda struck a supply agreement for their anemia drug Omontys with Fresenius. Item

> OncoMed Pharmaceuticals has kicked off a Phase I clinical trial for OMP-54F28 in patients with advanced solid tumors. The drug, which is designed to attack cancer stem cells, is being developed in partnership with Bayer Healthcare. News

Medical Devices News

@FierceMedDev: While purchasers praise the FDA's device ID plan, members of the industry remain wary. Item | Follow @FierceMedDev

@MarkHFierce: We have extended the nomination deadline for the 15 fiercest medical device developers to July 13. Spread the word. Survey | Follow @MarkHFierce

@DamianFierce: Devicemaker B. Braun is moving to block Fresenius' purchase of Germany's Rhoen. More | Follow @DamianFierce

> Sunshine Heart ($SSH) has seen its shares quadruple in value as shareholders learn about its investigational heart pump, C Pulse Heart Assist. News

> Quest Diagnostics ($DGX) plans to gain from Merck's ($MRK) plan to end testing of an experimental osteoporosis drug early because of its success in preventing hip fractures, The Wall Street Journal reports. That's because the company gets royalties on future sales of the drug. Roundup

> The U.S. spinal implant market should hit close to $7 billion by 2018, Research and Markets concludes in a new report. Release

> Thermo Fisher Scientific ($TMO) has declared a quarterly cash dividend of 13 cents per share. Release

> Sen. Scott Brown (R-MA) is urging his colleagues to take up the medical device tax repeal bill passed by the House last month, saying the 2.3% charge will cost thousands of jobs. More

And Finally... The rules are confusing about when a phone app, some tied to drug use, needs FDA approval. Story